Prevention of Hepatitis B in Travelers to Endemic Areas

  • F. E. André

Abstract

The latest World Health Organization estimate is that there are about 300 million chronic carriers of hepatitis B virus (HBV) worldwide [1]. Prevalence varies from between less than 1% in western Europe and North America, to 10%–20% in Asia and 7%–15% in parts of Africa [2–5]. Non-immune travellers to countries in areas with a high incidence of hepatitis B who reside in low-incidence countries are therefore at an increased risk of contracting an infection.

Keywords

Hepatitis Albumin Europe Nigeria Trop 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Anonymous (1988) Viral hepatitis. Weekly Epidemiol Rec 63:89–91Google Scholar
  2. 2.
    Sobeslavsky O (1980) Prevalence of markers of hepatitis B virus infection in various countries: a WHO collaborative study. Bull WHO 58:621–628PubMedGoogle Scholar
  3. 3.
    Lingao AL, Domingo EO, West S, Reyes CM, Gasmen S, Viterbo G, Tiu E, Lan-sang MA (1986) Seroepidemiology of hepatitis B virus in the Philippines. Am J Epidemiol 123:473–480PubMedGoogle Scholar
  4. 4.
    Lok AS-F, Lai C-L, Wu P-C, Wong VC-W, Yeoh E-K, Lin H-J (1987) Hepatitis B virus infection in Chinese families in Hong Kong. Am J Epidemiol 126:492–499PubMedGoogle Scholar
  5. 5.
    Gesemann M, Amazigo U, Marcus I, Dupasquier I, Staugard F, Scheiermann N (1987) Prevalence of hepatitis B virus markers and Delta antibodies in Nigeria and Botswana. Trop Med Parasitol 38:268–269Google Scholar
  6. 6.
    Sansonno DE, Manghisi OG (1987) Auto-antibody to human albumin after vaccination for hepatitis B infection. Ital J Gastroenterol 19:182–183Google Scholar
  7. 7.
    Wiedermann G, Scheiner O, Ambrosch F, Kraft B, Kollaritsch H, Kremsner P, Hauser P et al. (1988) Lack of induction of IgE and IgG antibodies to yeast in humans immunized with recombinant hepatitis B vaccines. Int Arch Allergy Appl Immunol 85:130–132PubMedCrossRefGoogle Scholar
  8. 8.
    Schellekens H, de Reus A, Peetermans JH, van Eerd PACM (1987) The protection of chimpanzees against hepatitis B viral infection using a recombinant yeast-derived hepatitis B surface antigen. Postgrad Med J 63 [Suppl 2]:93–96PubMedGoogle Scholar
  9. 9.
    André FE, Safary A (1987) Summary of clinical findings on Engerix-B, a genetically engineered yeast-derived hepatitis B vaccine. Postgrad Med J 63[Suppl 2]: 169–178PubMedGoogle Scholar
  10. 10.
    Stevens CE; Toy PT, Tong MJ, Taylor PE, Vyas GN, Nair PV, Gudavalli M, Krug-man S (1985) Perinatal hepatitis B virus transmission in the United States: prevention by passive-active immunization. JAMA 253:1740–1745PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1989

Authors and Affiliations

  • F. E. André

There are no affiliations available

Personalised recommendations